Meiji Seika Pharma will present 10 studies on Nacubactam at ESCMID Global 2026 including Phase III Integral-2 results in ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but turned down a rival product ...

Pune: An indigenously developed antibiotic has emerged as a "blessing" in the treatment of complicated urinary tract infections (UTIs) among Indian patients, said Dr V Balaji, professor of clinical ...

Review the side-effects of Cefepime as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Orchid Pharma Limited recently announced the launch of its new drug – Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), ...

Orchid Pharma Limited, a Chennai-based Indian pharmaceutical company, announced the launch of its new drug - cefepime-enmetazobactam, which has been approved for the treatment of complicated urinary ...

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South Africa. EXBLIFEP® has been approved by the U.S. Food and ...

Orchid Pharma on Thursday said it has received approval from regulator DCGI to manufacture and market an antibiotic drug for the treatment of complicated urinary tract infections. The Drug Controller ...

Chennai-based Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity active pharmaceutical ingredient (API ...

Indian pharma player Wockhardt Ltd has said that the Phase III clinical trial for Zaynich (Zidebactam/Cefepime) is making progress according to the schedule and is likely to complete by the first ...

People believed to have sepsis who take piperacillin-tazobactam (Zosyn) and vancomycin have a 5% absolute mortality increase at 90 days compared with those who take cefepime and vancomycin, a new ...

Over the last few days, as the FDA rejected one antibiotic combination treatment for complicated urinary tract infections (cUTIs), it has approved another. The United States regulator has signed off ...